Pneumococcal Infection Clinical Trial
Official title:
Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis. PneumoVas Pilot 1
Descriptive study of the residual anti-pneumococcal immunity in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who have previously gone through pneumococcal immunization.
Status | Completed |
Enrollment | 19 |
Est. completion date | August 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age = 18 years - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: diagnosis for granulomatosis with polyangiitis, microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis according to American College of Rheumatology criteria - Anti-pneumococcal immunization in the past 36 months - History of anti-pneumococcal vaccination according to French recommendations (simple vaccine schedule with PPV23 or combine vaccine schedule with PCV13 followed by PPV23 8 weeks later) Exclusion Criteria: - Known or suspected pregnancy - Splenectomy - Patient without social security coverage - Patient opposal |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
France | AP-HP ; Cochin Hospital | Paris | Ile de France |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Residual anti-pneumococcal immunity after pneumococcal immunization. | Proportion of patients at baseline (V0) with =1 µg/mL ELISA immunoglobulins G (IgG) antibody titers to at least 6 of the 10 shared serotypes (i.e. 3, 4, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) included both in the 13-valent conjugate pneumococcal vaccine (PCV13) and in the 23-valent non-conjugate pneumococcal vaccine (PPV23) | visit V0 (day 0) | No |
Secondary | To assess serotype 3, 4, 6B, 7F, 9V, 14, 18C, 19 A, 19F, 23F, 10A and 12F-specific residual immunity after vaccination | ELISA specific antibody titres to serotype 3, 4, 6B, 7F, 9V, 14, 18C, 19 A, 19F, 23F (included both in PCV13 and PPV23), 10A and 12F (specific to PPV23) | visit V0 (day 0), visit V-1 (pre immunization) | No |
Secondary | For each of the following serotypes (3, 4, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), to assess among ELISA-protected patients (i.e. with a =1 µg/mL ELISA IgG antibody titer) the proportion who also show in vitro opsonophagocytic antibody activity | Descriptive analysis: a/ For each of the following serotypes (3, 4, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), opsonophagocytosis (OPA) titers will be measured in ELISA-protected patients at V0. Opsonophagocytic antibody activity is considered positive if the antibody titer is above a serotype-specific predefined threshold. B/ The proportion of overall OPA-protected patients (meaning = 50% of OPA positive serotypes ) |
visit V0 (day 0) | No |
Secondary | For patients for whom pre-vaccinal serum is available (via the PHENOVASC bank), to assess the impact of immunization on serotype-specific ELISA antibody titer and OPA activity. | For patients already included in the PHENOVASC study (V-1) =6 months before receiving pneumococcal immunization, anti-pneumococcal immunity will be assessed for serotype 3 , 4 , 6B, 7F, 9V, 14 , 18C, 19A , 19F , 23F, 10A and 12F (with ELISA only for the two latter). For each serotype: In ELISA, we will describe the proportion of responding patients (i.e. with a two-fold increase from V-1 to VO and a =1 µg/ml titre at V0. In VO ELISA-responding patients, OPA titers will be measured. An opsonophagocytic antibody activity is considered positive if the antibody titer shows a four-fold increase from V-1 to V0 and is above a serotype-specific predefined threshold. |
visit V-1 (pre immunization) ; visit V0 (day 0) | No |
Secondary | Composite Outcome Measures - To identify epidemiologic, clinic and biologic predictive factors that may influence vaccine-induced immune response. | Analysis of epidemiological, clinical and biological data collected during follow-up: age, sex, history of immunosuppressive therapy, time since previous PPV23 injection, number of previous PPV23 immunizations, AAV activity and severity according to Birmingham Vasculitis Activity Score and Vasculitis Damage Index, results of biological analyses | visit V-1 (pre immunization) ; visit V0 (day 0) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03095326 -
Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia
|
Phase 4 | |
Completed |
NCT02260882 -
Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)
|
Phase 4 | |
Completed |
NCT02572635 -
A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax
|
Phase 1 | |
Completed |
NCT01654263 -
A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
|
Phase 2 | |
Completed |
NCT01531322 -
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00496093 -
Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)
|
Phase 3 | |
Completed |
NCT02062281 -
Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
|
Phase 4 | |
Completed |
NCT00133549 -
9-valent CRM 197 Pneumococcal
|
Phase 2 | |
Completed |
NCT03467984 -
A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants
|
Phase 2 | |
Active, not recruiting |
NCT03489018 -
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
|
Phase 4 | |
Recruiting |
NCT02463578 -
Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
|
N/A | |
Completed |
NCT00535730 -
ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)
|
Phase 3 | |
Completed |
NCT02558751 -
Pneumonia Vaccine in Aging HIV Positive Individuals
|
Phase 0 | |
Completed |
NCT02515240 -
Immune Response to Pneumococcal Vaccination in HIV Infected Individuals
|
Phase 0 | |
Completed |
NCT00560950 -
Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)
|
Phase 3 | |
Completed |
NCT05425732 -
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
|
Phase 3 | |
Completed |
NCT03619252 -
Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
|
Phase 4 | |
Not yet recruiting |
NCT03549208 -
A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults
|
Phase 1 | |
Not yet recruiting |
NCT03341195 -
Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan
|
N/A | |
Recruiting |
NCT06177912 -
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
|
Phase 3 |